Safinamide in the management of patients with Parkinson’s disease not stabilized on levodopa: a review of the current clinical evidence

References

• ConnollyBSLangAEPharmacological treatment of Parkinson disease: a reviewJAMA2014311161670168324756517
   PubMed Web of Science ®Google Scholar
• MüllerTFoleyPClinical Pharmacokinetics and Pharmacodynamics of SafinamideClin Pharmacokinet201756325126127665574
   PubMed Web of Science ®Google Scholar
• RiedererPGerlachMMüllerTReichmannHRelating mode of action to clinical practice: dopaminergic agents in Parkinson’s diseaseParkinsonism Relat Disord200713846647917919963
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationFDA approves drug to treat Parkinson’s disease [press release]Silver Spring, MDUS Food and Drug Administration2017321 Available from: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm547852.htmAccessed June 28, 2018
   Google Scholar
• CacciaCMajRCalabresiMMaestroniSSafinamide: from molecular targets to a new anti-Parkinson drugNeurology2006677 Suppl 2S18S2317030736
   PubMed Web of Science ®Google Scholar
• MarzoAdal BoLMontiNCPharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activityPharmacol Res2004501778515082032
   PubMed Web of Science ®Google Scholar
• Seithel-KeuthAJohneAFreislebenAAbsolute Bioavailability and Effect of Food on the Disposition of Safinamide Immediate Release Tablets in Healthy Adult SubjectsClin Pharmacol Drug Dev201321798927121562
   PubMed Web of Science ®Google Scholar
• LeurattiCSardinaMVenturaPDisposition and metabolism of safinamide, a novel drug for Parkinson’s disease, in healthy male volunteersPharmacology2013923–420721624136086
   PubMed Web of Science ®Google Scholar
• DeeksEDSafinamide: first global approvalDrugs201575670571125851099
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationXadago (safinamide): Clinical pharmacology biopharmaceutics review(s)FDA2017 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000TOC.cfmAccessed June 28, 2018
   Google Scholar
• European Medicines AgencySafinamide: Summary of product characteristicsEMA2014 Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002396/human_med_001847.jsp&mid=WC0b01ac058001d124Accessed June 28, 2018
   Google Scholar
• Xadago^® (safinamide) [package insert]Louisville, KYUS WorldMeds2017
   Google Scholar
• AkaoYMaruyamaWYiHShamoto-NagaiMYoudimMBNaoiMAn anti-Parkinson’s disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cellsNeurosci Lett2002326210510812057839
   PubMed Web of Science ®Google Scholar
• AkaoYMaruyamaWShimizuSYiHMitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, n-propargyl-1(r)-aminoindanJ Neurochem200282491392312358797
   PubMed Web of Science ®Google Scholar
• MüllerTPrzuntekHRieksMMackowiakASelegiline reduces cisplatin-induced neuronal death in neuroblastoma cellsNeurol Res200830441741918237459
   PubMed Web of Science ®Google Scholar
• SadeghianMMullaliGPocockJMNeuroprotection by safinamide in the 6-hydroxydopamine model of Parkinson’s diseaseNeuropathol Appl Neurobiol201642542343526300398
   PubMed Web of Science ®Google Scholar
• BindaCWangJPisaniLStructures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogsJ Med Chem200750235848585217915852
   PubMed Web of Science ®Google Scholar
• di StefanoAFRuscaAPressor response to oral tyramine during co-administration with safinamide in healthy volunteersNaunyn Schmiedebergs Arch Pharmacol2011384650551521850574
   PubMed Web of Science ®Google Scholar
• MarquetAKupasKJohneAThe effect of safinamide, a novel drug for Parkinson’s disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trialClin Pharmacol Ther201292445045722948897
   PubMed Web of Science ®Google Scholar
• CattaneoCCacciaCMarzoAMajRFarielloRGPressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibitionClin Neuropharmacol200326421321712897643
   PubMed Web of Science ®Google Scholar
• AmbroziLDanielczykWTreatment of impaired cerebral function in psychogeriatric patients with memantine – results of a phase II double-blind studyPharmacopsychiatry19882131441463406051
   PubMed Web of Science ®Google Scholar
• BaronePCattaneoCLa FerlaRBonnizoniESardinaMSignificant reduction of pain treatments with safinamide administered as add-on therapy to levodopa in patients with parkinson’s disease and fluctuation [abstract]Mov Disord201522Suppl 1293
   Google Scholar
• KrösserSMarquetAGallemannDEffects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjectsBiopharm Drug Dispos201233955055923097240
   PubMed Web of Science ®Google Scholar
• BorgohainRSzaszJStanzionePRandomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuationsMov Disord201429222923724323641
   PubMed Web of Science ®Google Scholar
• SchapiraAHFoxSHHauserRAAssessment of Safety and Effi-cacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical TrialJAMA Neurol201774221622427942720
   PubMed Web of Science ®Google Scholar
• CattaneoCSardinaMBonizzoniESafinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson’s Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLEJ Parkinsons Dis20166116517326889632
   PubMedGoogle Scholar
• BorgohainRSzaszJStanzionePTwo-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson’s diseaseMov Disord201429101273128025044402
   PubMed Web of Science ®Google Scholar
• CattaneoCFerlaRLBonizzoniESardinaMLong-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson’s Disease: A Post-Hoc AnalysisJ Parkinsons Dis20155347548126406127
   PubMedGoogle Scholar
• StocchiFArnoldGOnofrjMKwiecinskiHImprovement of motor function in early Parkinson disease by safinamideNeurology200463474674815326260
   PubMed Web of Science ®Google Scholar
• StocchiFBorgohainROnofrjMA randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson’s disease patientsMov Disord201227110611221913224
   PubMed Web of Science ®Google Scholar
• BaronePFernandezHFerreiraJSafinamide as add-on therapy to a stable dose of a single dopamine agonist: Results from a randomized, placebo-controlled, 24-week multicenter trial in early idiopathic parkinson disease (PD) patients (MOTION study)Neurology2013807 Supp1
   Google Scholar
• SchapiraAHStocchiFBorgohainRLong-term efficacy and safety of safinamide as add-on therapy in early Parkinson’s diseaseEur J Neurol201320227128022967035
   PubMed Web of Science ®Google Scholar
• PagonabarragaJKulisevskyJSafinamide from daily clinical practice: first clinical stepsRev Neurol2017651043343829130466
   PubMed Web of Science ®Google Scholar
• ManciniFdi FonzoALazzeriGReal life evaluation of safinamide effectiveness in Parkinson’s diseaseNeurol Sci201839473373929441484
   PubMed Web of Science ®Google Scholar
• United States Department of Health and Human Services Food and Drug AdministrationNew drug application approval, NDA 207145: Xadago (safinamide)Silver Spring, MDFood and Drug Administration2017 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/207145Orig1s000ltr.pdfAccessed June 28, 2018
   Google Scholar
• European CommissionEuropean Medicines AgencyEPAR summary for the public: Xadago (safinamide)European Medicines Agency2015 Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002396/human_med_001847.jsp&mid=WC0b01ac058001d124Accessed June 28, 2018
   Google Scholar
• BlairHADhillonSSafinamide: A Review in Parkinson’s DiseaseCNS Drugs201731216917628110399
   PubMed Web of Science ®Google Scholar
• DesouzaRMSchapiraASafinamide for the treatment of Parkinson’s diseaseExpert Opin Pharmacother201718993794328504022
   PubMed Web of Science ®Google Scholar